Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Neoplasms 28Neoplasm Metastasis 26Colorectal Neoplasms 26Recurrence 22Ovarian Neoplasms 22Pancreatic Neoplasms 21Prostatic Neoplasms 20Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 19Melanoma 18Glioblastoma 16Lymphoma, Large B-Cell, Diffuse 14Lung Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Multiple Myeloma 13Lymphoma, Non-Hodgkin 13Endometrial Neoplasms 13Triple Negative Breast Neoplasms 12Colonic Neoplasms 12Carcinoma, Renal Cell 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Glioma 10Gastrointestinal Neoplasms 10Rectal Neoplasms 9Lymphoma, Follicular 9Lymphoma 9Head and Neck Neoplasms 9Small Cell Lung Carcinoma 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pituitary ACTH Hypersecretion × 30 days × Clear all
NCT05804669 2026-06-04

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Crinetics Pharmaceuticals Inc.

Phase 1/2 Recruiting
18 enrolled
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡